APA (7th ed.) Citation

GA, P., RK, A., C, C., RF, D., S, H., J, M., . . . DJ, W. (2024). Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 78(3), 562. https://doi.org/10.1093/cid/ciad709

Chicago Style (17th ed.) Citation

GA, Papanicolaou, et al. "Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 78, no. 3 (2024): 562. https://doi.org/10.1093/cid/ciad709.

MLA (9th ed.) Citation

GA, Papanicolaou, et al. "Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 78, no. 3, 2024, p. 562, https://doi.org/10.1093/cid/ciad709.